US Centers for Disease Control and Prevention (CDC) increases US blood monitoring:
This article was originally published in Clinica
The US Centers for Disease Control and Prevention (CDC) says that the US blood supply is "faced increasingly with new and re-emerging infectious disease challenges". Though the CDC is increasing its surveillance to protect against new blood contaminants, it regards haemophiliacs as the best early indicators of a problem, due to their use of substantial amounts of human blood-derived clotting factors.
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.